



LB Pharmaceuticals, Inc. Appoints Robert R. Ruffolo, Jr., Ph.D. to its Board of Directors

Dr. Ruffolo brings more than 40 years of pharmaceutical company leadership and product development experience to LB

New York, NY (July 8th, 2019) – LB Pharmaceuticals, Inc., (“LB”, or the “Company”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, , today announced the appointment of Robert (Bob) R. Ruffolo, Jr., Ph.D., to its Board of Directors, effective immediately. Additionally, Isaac Blech has recently stepped down from the Company’s Board for personal reasons.

“On behalf of LB Pharmaceuticals and its Board of Directors, I am pleased to welcome Dr. Ruffolo to our Board,” stated **Zachary Prensky, President and CEO**. “With a career spanning over four decades in the Pharmaceutical industry, Bob is an accomplished leader with a rare blend of scientific expertise, and commercial success.”

“I am excited to join the LB Pharmaceuticals Board,” added **Dr. Ruffolo**. “LB-102 is an exciting new molecule that has the potential to improve the quality of care for thousands of US schizophrenia patients who are not being adequately treated by existing therapeutic options. Benzamides have played an important role in Europe for decades and I am thrilled to be working with a team devoted to bringing this option to US patients.”

Dr. Ruffolo served as the President of R&D and Senior Vice President of Wyeth Pharmaceuticals (now, Pfizer) from 2002 to 2008. Prior to Wyeth, Bob was Senior Vice President in R&D at SmithKline Beecham Pharmaceuticals (now GSK) for 17 years. Bob played a significant role in the discovery and/or development of a number of marketed products, including carvedilol, ropinerole, dobutamine, and eprosartan, among others. He has been recognized with several prestigious awards, including the Discoverer's Award in 2008, for his pioneering work on the discovery of carvedilol for the treatment of congestive heart failure. Bob currently serves as a Director at Sigilon Therapeutics, Elucida Oncology, Sapience Therapeutics and Aridis Pharmaceuticals. He is also the President of Ruffolo Consulting LLC, a position he has held since 2008.

Dr. Ruffolo holds a B.S. degree in Pharmacy, and a Ph.D. degree in Pharmacology, both from The Ohio State University.

About LB Pharmaceuticals

LB is a development stage CNS-focused life science company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed, in the United States. Our approach is to create a research-focused organization dedicated to generating novel intellectual property around improved versions of these former best-selling drugs. We have a low-risk, high-reward drug development business plan: Invest in bringing to the US market patented, branded, first-to-market versions of standard-of-care CNS therapies currently in use worldwide

Contact

Zachary Prensky, President & CEO

Zach@LBPharma.us (212) 605-0230

575 Madison Avenue, 10th Floor NY NY 10022